文献速递细菌感染、耐药与抗菌药物

甲氧西林敏感与耐药金黄色葡萄球菌菌血症:美国全国性30天再入院、院内死亡、住院时长与费用估计

Methicillin-susceptible and Methicillin-resistant Staphylococcus aureus Bacteremia: Nationwide Estimates of 30-Day Readmission, In-hospital Mortality, Length of Stay, and Cost in the United States.
PubMed 文献 · Clin Infect Dis · 2019-01-01

基于2014年美国全国再入院数据库(覆盖49.3%美国住院)的回顾性分析,纳入年龄≥18岁的金黄色葡萄球菌菌血症患者92 089例(标准误1905),其中48.5%(标准误0.4%)为MRSA菌血症。总体30天再入院率为22%(标准误0.3),MRSA与MSSA无差异,但MRSA菌血症再入院时菌血症复发更多(HR 1.17,95%CI 1.02-1.34)、院内死亡更高(OR 1.15,95%CI 1.07-1.23)、住院更长(IRR 1.09,95%CI 1.06-1.11)。

要点

  • 金黄色葡萄球菌菌血症30天再入院常见且费用高,MRSA与MSSA再入院率无差异。
  • MRSA菌血症再入院时菌血症复发风险更高(HR 1.17),院内死亡更高(OR 1.15)。
  • 心内膜炎、免疫抑制合并症和药物滥用者再入院时菌血症复发更常见。

核心结论

  • 金黄色葡萄球菌菌血症后30天再入院常见且费用高。
  • MRSA菌血症与再入院时菌血症复发、死亡率升高和住院时间延长相关。
  • 应继续优化患者管理,尤其针对有危险因素者,以减少再入院及相关患病与死亡。

研究设计与样本

  • 回顾性分析,使用2014年美国全国再入院数据库,覆盖49.3%的美国住院。
  • 通过ICD-9-CM识别年龄≥18岁的MSSA与MRSA菌血症患者。
  • 采用Cox比例风险回归、logistic回归、Poisson回归及伽马分布对数链接的广义线性模型评估结局。

主要发现

  • 金黄色葡萄球菌菌血症患者92 089例(标准误1905),48.5%(标准误0.4%)为MRSA菌血症。
  • 总体30天再入院率22%(标准误0.3),MRSA与MSSA之间无差异。
  • MRSA菌血症再入院时菌血症复发HR 1.17(95%CI 1.02-1.34)。
  • MRSA菌血症院内死亡OR 1.15(95%CI 1.07-1.23)。
  • MRSA菌血症住院时长IRR 1.09(95%CI 1.06-1.11)。

关键数值与推荐

  • 总体再入院费用每例12 425美元(标准误174美元)。
  • 菌血症复发者再入院费用每例19 186美元(标准误623美元)。
  • 再入院时菌血症复发在心内膜炎、免疫抑制合并症和药物滥用患者中尤为常见。

临床怎么用

  • 对金黄色葡萄球菌菌血症出院患者应关注30天再入院风险与费用负担。
  • MRSA菌血症患者需警惕再入院时菌血症复发、院内死亡与住院时间延长。
  • 对合并心内膜炎、免疫抑制合并症或药物滥用者应加强出院后管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Information on outcomes of methicillin-susceptible and -resistant Staphylococcus aureus (MSSA and MRSA, respectively) bacteremia, particularly readmission, is scarce and requires further research to inform optimal patient care. METHODS: We performed a retrospective analysis using the 2014 Nationwide Readmissions Database, capturing 49.3% of US hospitalizations. We identified MSSA and MRSA bacteremia using International Classification of Diseases, Ninth Revision, Clinical Modification among patients aged ≥18 years. Thirty-day readmission, mortality, length of stay, and costs were assessed using Cox proportional hazards regression, logistic regression, Poisson regression, and generalized linear model with gamma distribution and log link, respectively. RESULTS: Of 92 089 (standard error [SE], 1905) patients with S. aureus bacteremia, 48.5% (SE, 0.4%) had MRSA bacteremia. Thirty-day readmission rate was 22% (SE, 0.3) overall with no difference between MRSA and MSSA, but MRSA bacteremia had more readmission for bacteremia recurrence (hazard ratio, 1.17 [95% confidence interval {CI}, 1.02-1.34]), higher in-hospital mortality (odds ratio, 1.15 [95% CI, 1.07-1.23]), and longer hospitalization (incidence rate ratio, 1.09 [95% CI, 1.06-1.11]). Readmission with bacteremia recurrence was particularly more common among patients with endocarditis, immunocompromising comorbidities, and drug abuse. The cost of readmission was $12 425 (SE, $174) per case overall, and $19 186 (SE, $623) in those with bacteremia recurrence. CONCLUSIONS: Thirty-day readmission after S. aureus bacteremia is common and costly. MRSA bacteremia is associated with readmission for bacteremia recurrence, increased mortality, and longer hospitalization. Efforts should continue to optimize patient care, particularly for those with risk factors, to decrease readmission and associated morbidity and mortality in patients with S. aureus bacteremia.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Inagaki K, Lucar J, Blackshear C, et al. Methicillin-susceptible and Methicillin-resistant Staphylococcus aureus Bacteremia: Nationwide Estimates of 30-Day Readmission, In-hospital Mortality, Length of Stay, and Cost in the United States. Clin Infect Dis. 2019. PMID: 30753447. doi:10.1093/cid/ciz123

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。